A COVID Prevention Pill Nears a First-of-Its-Kind FDA Decision

For more than five years, the standard advice after a close brush with COVID-19 has been some version of wait and watch. Test in a few days. Mask around vulnerable family members. Hope the infection does not take hold. There has never been a medicine a person could simply take to keep the virus from gaining a foothold after a known exposure. That gap is now at the center of a regulatory decision the Food and Drug Administration is expected to reach around June 16, one that could reshape how households respond the moment someone tests positive.

The drug under review is ensitrelvir, an oral antiviral developed by the Japanese pharmaceutical company Shionogi and sold in Japan under the brand name Xocova. If the FDA clears it, ensitrelvir would become the first oral medication approved in the United States for the prevention of COVID-19 after exposure, a use known in medicine as post-exposure prophylaxis. No such pill exists today.

What Ensitrelvir Actually Does Inside the Body

Ensitrelvir belongs to a class of drugs called 3CL protease inhibitors, sometimes described as main protease inhibitors. The coronavirus relies on an enzyme called the main protease to cut its newly made proteins into working pieces, a step the virus cannot skip if it wants to copy itself. Ensitrelvir jams that enzyme, halting replication before the virus can establish a meaningful infection.

That mechanism is not new in concept. The active ingredient in Paxlovid, nirmatrelvir, targets the same enzyme. What sets ensitrelvir apart is how it is given. The regimen is once daily for five days: a 375 milligram loading dose on the first day, followed by 125 milligrams on days two through five. Shionogi first won emergency approval for the drug in Japan in November 2022, secured a full treatment approval there in 2024, and in March 2026 added a Japanese indication specifically for post-exposure prevention.

Inside SCORPIO-PEP, the Trial That Made the Case

The application rests on a large, rigorously designed study called SCORPIO-PEP, a global, double-blind, randomized, placebo-controlled phase 3 trial conducted between June 2023 and September 2024. Researchers enrolled household contacts of people who had just developed symptomatic COVID-19, screening participants to confirm they had not yet tested positive themselves. The trial ultimately involved 2,387 participants aged 12 and older, with 2,041 included in the primary analysis.

The results were striking. By day 10, just 2.9 percent of participants who took ensitrelvir had developed symptomatic COVID-19, compared with 9.0 percent of those who received placebo. That works out to roughly a 67 percent reduction in the risk of symptomatic illness, with a risk ratio of 0.33. The benefit appeared even larger among people at high risk of severe disease, where the reduction reached about 76 percent. The findings were published in The New England Journal of Medicine in May.

The drug was also well tolerated. Adverse event rates were nearly identical between the two groups, 15.1 percent for ensitrelvir versus 15.5 percent for placebo, and crucially, participants did not report the altered or metallic taste that has frustrated many Paxlovid users.

How Prevention After Exposure Would Work in Practice

Post-exposure prophylaxis is a familiar idea in other corners of medicine. People exposed to HIV, rabies, or whooping cough are routinely given medication to head off infection. Applying the concept to COVID-19 would change the choreography of a household exposure. Instead of waiting to see whether a sore throat turns into a positive test, a person who has been in close contact with an infected family member could begin a short course of pills aimed at stopping the infection before symptoms ever appear.

In SCORPIO-PEP, participants began treatment within 72 hours of exposure. Frederick Hayden, a professor emeritus at the University of Virginia who has studied the data, summarized the effect plainly. "People taking ensitrelvir within 72 hours after household exposure were three times less likely to develop COVID-19 compared with those given placebo," he said. Aeron Hurt, vice president of global medical science at Shionogi, framed the magnitude in similar terms. "Ensitrelvir cuts the chances of developing COVID-19 by two-thirds, which is substantial," he said.

Why It Is Not Simply Another Paxlovid

Paxlovid, the most widely used oral COVID antiviral in the United States, is approved to treat infection, not to prevent it, and a 2022 trial of Paxlovid for post-exposure prevention failed to hit its primary goal. The two drugs also differ in design in ways that matter at the pharmacy counter.

Paxlovid pairs nirmatrelvir with a second drug, ritonavir, whose job is to slow the body's metabolism of the antiviral so it stays effective. Ritonavir is a powerful inhibitor of the CYP3A4 enzyme system that breaks down roughly 60 percent of all medications, which is why Paxlovid carries a long list of drug interactions. Many older and medically fragile patients, precisely those who would benefit most, cannot take it because it clashes with their existing prescriptions. Ensitrelvir does not require ritonavir and is taken once a day rather than twice, lowering the daily pill burden.

Ensitrelvir is not free of interaction concerns. It is itself a strong CYP3A inhibitor, an effect researchers expect to fade roughly 10 days after the last dose, so its labeling will still demand attention to other medications. But the absence of ritonavir, the simpler schedule, and the lack of taste disturbance give it a meaningfully different profile.

What Approval Would Mean for Public Health

The practical appeal is easy to see. A pill that interrupts transmission inside a household could protect the elderly, the immunocompromised, and others for whom even a mild infection carries real danger. It could blunt the secondary spread that turns one case into three, and it would hand clinicians a tool they have never had: something concrete to offer the worried family member standing in the doorway.

Open questions remain. Regulators and physicians will weigh how the drug should be deployed responsibly, given that overuse of any antiviral can encourage resistance. Pricing, insurance coverage, and how quickly prescribing guidelines adapt will all shape whether a clearance translates into real-world impact. And the trial measured prevention of symptomatic illness over 10 days, leaving longer-term and broader population effects to be studied further.

For now, the decision belongs to the FDA, and the calendar points to mid-June. Whatever the agency concludes, ensitrelvir has already demonstrated something that eluded earlier candidates, that a short course of pills can measurably lower the odds of getting sick after exposure to the virus. If the approval comes, the question facing an exposed household may soon shift from whether anything can be done to whether to reach for the medicine cabinet.